跳至主要内容
临床试验/CTIS2023-504637-42-01
CTIS2023-504637-42-01进行中(未招募)1 期

Personalized, CT-guided antithrombotic therapy versus lifelong single antiplatelet therapy to reduce thromboembolic and bleeding events in non-atrial fibrillation patients after transcatheter aortic valve implantation: a pragmatic, international, multicentre, randomized clinical trial (POPular ATLANTIS trial)

St Antonius Hospital0 个研究点目标入组 1,950 人开始时间: 2023年8月7日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
1,950

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
65 至 65+(—)
性别
All

入选标准

  • Successful TAVI (according to the VARC-3 criteria) with any approved device, Ability to understand and to comply with the study protocol, Written informed consent

排除标准

  • Existing indication for oral anticoagulation (e.g. atrial fibrillation, obstructive valve thrombosis detected by echocardiography prior to inclusion), Creatinine clearance <15 mL/min (based on the CKD-EPI formula) or on renal replacement therapy

研究者

相似试验